A four-unit peptide built in Russia from a liver extract, proposed to loosen the packed genetic material of ageing cells. Measured only in cells from older donors and in old rats, never as a health outcome in a living person. Risks are unmeasured, not absent. Supply runs entirely through unregulated sellers. An unresolved question, not a supported choice. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT | 10–26 U/L men, 10–19 U/L women | Detects liver cell injury, the target organ |
| AST | 10–26 U/L | Confirms whether an enzyme rise is liver or muscle |
| GGT | Below 20 U/L men, below 15 U/L women | Most sensitive early marker of liver stress and bile flow |
| ALP | 60–90 U/L | Flags bile duct obstruction and bone turnover |
| Total bilirubin | 0.4–1.0 mg/dL | Reflects overall liver clearance capacity |
| Albumin | 4.2–5.0 g/dL | Reflects the liver's synthetic capacity, the function Livagen targets |
| hs-CRP | Below 0.5 mg/L | Tracks the inflammatory status the animal work claims is normalised |
| Complete blood count with differential | Lymphocytes 1.5–3.0 ×10⁹/L, neutrophils 2.0–4.0 ×10⁹/L | Detects marrow effects no trial has excluded, and tracks the claimed immune effect |
| Ferritin | 50–100 ng/mL men, 30–80 ng/mL women | Iron overload is a common confounder of raised liver enzymes |
| Epigenetic age acceleration | No established target exists for this measure; track the change from the individual's own baseline instead | It is the outcome the proposed mechanism most directly predicts |
Cadence: Baseline before starting; liver panel and blood count 2 to 4 weeks after a course ends, then at 3 months, then every 6 to 12 months if courses continue. Inflammatory markers and iron stores follow the 3-month and annual timepoints; epigenetic age is interpretable only at 6 to 12-month intervals.